文献速递生殖医学

人胚胎代谢成像可预测倍性状态但与临床妊娠结局无关:一项先导试验

Metabolic imaging of human embryos is predictive of ploidy status but is not associated with clinical pregnancy outcomes: a pilot trial.
PubMed 文献 · Hum Reprod · 2024-01-01

该先导试验纳入121对IVF夫妇,对105对夫妇的优质囊胚在复苏后行6分钟荧光寿命成像显微镜(FLIM)代谢扫描后再移植,结果显示代谢成像参数在导致妊娠与未妊娠的优质囊胚间无显著差异(ROC AUC 0.58),但区分倍性状态等其它因素AUC较高。

要点

  • FLIM代谢成像参数在导致妊娠与未妊娠的优质囊胚间无显著差异,ROC AUC为0.58。
  • FLIM可高度区分囊胚倍性状态:非整倍体(n=158) vs 整倍体及阳性妊娠胚胎(n=108)AUC=0.82。
  • 作者认为该先导试验提示代谢成像尚不能作为有效的胚胎活力检测工具,可能因线粒体代谢在着床后扮演其他角色。

核心结论

  • FLIM未能区分导致妊娠与未导致妊娠的优质囊胚之间一致的线粒体代谢模式,但可高度区分囊胚倍性状态;作者认为该先导试验提示代谢成像尚不能作为有效的胚胎活力检测工具。

研究设计与样本

  • 先导试验纳入121对IVF夫妇,其中105对夫妇的优质囊胚在复苏后于控温控气环境中行6分钟非侵入性FLIM代谢扫描,随后不作管理干预直接移植。
  • 另对158枚去标识的废弃非整倍体人胚胎进行测量,以量化与倍性状态等因素的相关性。
  • 统计采用逻辑回归和受试者工作特征(ROC)曲线,5折交叉验证在100次重复随机抽样上取平均,以AUC量化区分能力。

主要发现

  • 导致妊娠与未导致妊娠的优质囊胚之间,无任何代谢成像参数显示显著差异。
  • 使用代谢数据与元数据的逻辑回归所得ROC AUC为0.58。
  • 第5天囊胚(n=64) vs 第6天囊胚(n=41)的AUC=0.78;内细胞团 vs 滋养外胚层(n=105)的AUC=0.88;非整倍体(n=158) vs 整倍体及阳性妊娠胚胎(n=108)的AUC=0.82。

关键数值与推荐

  • 每枚囊胚获取8项代谢参数:NAD(P)H 4项与FAD 4项,分别为短和长荧光寿命、荧光强度及与酶结合的分子分数;并计算氧化还原比率(NAD(P)H强度/FAD强度)。

临床怎么用

  • 研究方案未按代谢成像结果选择移植胚胎,所有FLIM评估的囊胚均不作管理干预直接移植,作者认为该先导试验提示其尚不能作为有效的胚胎活力检测工具。

局限性

  • 研究方案未选择移植哪一枚胚胎,纳入的105枚囊胚均为优质囊胚。
  • 研究在参与者和研究站点数量上有限。
  • 增加统计效能并在更多站点开展试验,可能就FLIM临床应用的價值给出更强结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does fluorescence lifetime imaging microscopy (FLIM)-based metabolic imaging assessment of human blastocysts prior to frozen transfer correlate with pregnancy outcomes? SUMMARY ANSWER: FLIM failed to distinguish consistent patterns in mitochondrial metabolism between blastocysts leading to pregnancy compared to those that did not. WHAT IS KNOWN ALREADY: FLIM measurements provide quantitative information on NAD(P)H and flavin adenine dinucleotide (FAD+) concentrations. The metabolism of embryos has long been linked to their viability, suggesting the potential utility of metabolic measurements to aid in selection. STUDY DESIGN, SIZE, DURATION: This was a pilot trial enrolling 121 IVF couples who consented to have their frozen blastocyst measured using non-invasive metabolic imaging. After being warmed, 105 couples' good-quality blastocysts underwent a 6-min scan in a controlled temperature and gas environment. FLIM-assessed blastocysts were then transferred without any intervention in management. PARTICIPANTS/MATERIALS, SETTING, METHODS: Eight metabolic parameters were obtained from each blastocyst (4 for NAD(P)H and 4 for FAD): short and long fluorescence lifetime, fluorescence intensity, and fraction of the molecule engaged with enzyme. The redox ratio (intensity of NAD(P)H)/(intensity of FAD) was also calculated. FLIM data were combined with known metadata and analyzed to quantify the ability of metabolic imaging to differentiate embryos that resulted in pregnancy from embryos that did not. De-identified discarded aneuploid human embryos (n = 158) were also measured to quantify correlations with ploidy status and other factors. Statistical comparisons were performed using logistic regression and receiver operating characteristic (ROC) curves with 5-fold cross-validation averaged over 100 repeats with random sampling. AUC values were used to quantify the ability to distinguish between classes. MAIN RESULTS AND THE ROLE OF CHANCE: No metabolic imaging parameters showed significant differences between good-quality blastocysts resulting in pregnancy versus those that did not. A logistic regression using metabolic data and metadata produced an ROC AUC of 0.58. In contrast, robust AUCs were obtained when classifying other factors such as comparison of Day 5 (n = 64) versus Day 6 (n = 41) blastocysts (AUC = 0.78), inner cell mass versus trophectoderm (n = 105: AUC = 0.88) and aneuploid (n = 158) versus euploid and positive pregnancy embryos (n = 108) (AUC = 0.82). LIMITATIONS, REASONS FOR CAUTION: The study protocol did not select which embryo to transfer and the cohort of 105 included blastocysts were all high quality. The study was also limited in number of participants and study sites. Increased power and performing the trial in more sites may have provided a stronger conclusion regarding the merits of the use of FLIM clinically. WIDER IMPLICATIONS OF THE FINDINGS: FLIM failed to distinguish consistent patterns in mitochondrial metabolism between good-quality blastocysts leading to pregnancy compared to those that did not. Blastocyst ploidy status was, however, highly distinguishable. In addition, embryo regions and embryo day were consistently revealed by FLIM. While metabolic imaging detects mitochondrial metabolic features in human blastocysts, this pilot trial indicates it does not have the potential to serve as an effective embryo viability detection tool. This may be because mitochondrial metabolism plays an alternative role post-implantation. STUDY FUNDING/COMPETING INTEREST(S): This study was sponsored by Optiva Fertility, Inc. Boston IVF contributed to the clinical site and services. Becker Hickl, GmbH, provided the FLIM system on loan. T.S. was the founder and held stock in Optiva Fertility, Inc., and D.S. and E.S. had options with Optiva Fertility, Inc., during this study. TRIAL REGISTRATION NUMBER: The study was approved by WCG Connexus IRB (Study Number 1298156).

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Sakkas D, Gulliford C, Ardestani G, et al. Metabolic imaging of human embryos is predictive of ploidy status but is not associated with clinical pregnancy outcomes: a pilot trial. Hum Reprod. 2024. PMID: 38195766. doi:10.1093/humrep/dead268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。